Tampilkan postingan dengan label drug prices. Tampilkan semua postingan
Tampilkan postingan dengan label drug prices. Tampilkan semua postingan

Kamis, 22 Juni 2017

Lowering drug prices by raising drug prices.

Today's Managing Health Care Costs Number is 1/6


Kaiser Health News and the New York Times have reported on the four page Trump executive order to decrease drug prices.    He's going for irony -- he will decrease drug prices by raising them.

The recommendation comes from Trump's Drug Pricing and Innovation Workgroup, which is chock full of pharma industry executives.  As Kaiser Health News reports:

To solve the crisis of high drug prices, the group discussed strengthening the monopoly rights of pharmaceuticals overseas, ending discounts for low-income hospitals and accelerating drug approvals by the Food and Drug Administration. 

So - the administration thinks that if pharma companies are able to earn more dollars in India or Brazil they will lower their prices in the US?    That's simply not how pricing works!  The pharmaceutical companies have been plenty profitable overall and that has not led to any relief of steady price inflation.  Drug companies charge what the market will pay - and allowing them higher profits in one arena doesn't simply lower prices somewhere else. New oncology and specialty drugs routinely cost over $100,000 a year, and price increases on existing medications continue to outpace inflation.

The Administration would also decrease 340b discounts to hospitals and providers who serve low income communities.   Exactly how that would help drug prices?   It would increase pharmaceutical industry profitability allowing the drug companies to lower their prices overall.   Does anyone really believe that?

There's more.   The executive order could allow pharmaceutical companies to provide marketing material to insurers and pharmacy benefit managers before FDA approval, and "use less rigorous clinical trial standards to speed drug approvals."  I can see how this could decrease value (encouraging the use of new expensive drugs with little or no benefit beyond older established drugs).  But I can't see how this will decrease cost!

The FDA released a blog post promising action to prevent brand name legal tactics that delay introduction of generic medications.  That is one element of the Trump plan that could lead to some price relief.   However, the problem we face is the cost of brand name drugs.  We should push to get faster approval for generics, and we should allow importation of generics from other developed countries when we face shortages in the US. 

But we need action to decrease the price of new medications.   There are potential answers out there:
  • Medicare could negotiate prices (prohibited by the Medicare Part D enabling legislation).
  • The FDA could consider cost in drug approval (prohibited by current rules). 
  • The National Institutes of Health could "march in" and retake patents for drugs which are priced too high
  • We could implement an excise tax on excessive prices.  We could enable payments for expensive effective medications over the period of benefit rather than "up front."  

Here are a set of recommendations from Consumer Reports

But the Trump Administration drug plan is the answer to the pharmaceutical industry's wish list. It will raise overall drug costs abroad through actions to protect patents, and it will raise overall drug costs here by cracking down on 340b discounts. 

Rabu, 12 Oktober 2016

How the pharmacy dollar is divided


Today’s Managing Health Care Costs Number is 15.5%


Distribution of Payment for a Drug



Pharmacy costs are escalating rapidly, and we often focus on the brand name pharmaceutical companies.  Many of these companies have rapidly inflated their prices, often on drugs that are close to losing their patent protection, and where any past research investment has long ago been paid off.

Julie Appleby of Kaiser Health News put together an infographic last week that explains how many dollars are siphoned off at each stage of drug distribution, using a hypothetical brand name drug with a “list” wholesale price of $250.   I’ve been noodling with this for a number of days to figure out, in her example, who really makes what money when this prescription is filled?

First of all – on the “sources” side, the employer is paying $182 and the patient is paying $25 – so the total amount spent on the drug  is $207.   The  list price “wholesale acquisition cost, or WAC is $250 and the AWP is $300 (AWP stands for  “average wholesale price,” or as Appleby says “ain’t what’s paid”.)

Now- how is that $207 split up?

The Pharmacy Benefit Manager (likely CVS Caremark, Express Scripts, or Optum Rx) is paid $15.50, the wholesaler is paid $2.50, and the pharmacy is paid $14. This leaves $175 for the pharmaceutical company.   The total amount taken by intermediaries is $32, or 15.5% of the total paid by the employer and the patient.


This isn’t necessarily high – remember that this 15% is not pure profit.  Pharmacies have to keep the lights on, PBMs have to  contract with the pharmaceutical companies and manage claims, and wholesalers have to get the drug to the pharmacy.  We often pay more than 15% of the cost of acquisition of a product to middlemen –whether they are auto dealers or grocery stores.

But as drug prices increase, the absolute amount paid to intermediaries has continued to increase, even while the resource costs expended by each intermediary has not increased at such a rapid clip.  Appleby’s graphic shows us at least one reason why intermediaries are not exactly bummed out at rapid drug price increases.

Senin, 26 September 2016

Insurers block drug abuse medications


Today’s Managing Health Care Costs Number is $15,000





USA Today and the Cincinnati Enquirer have a heart-wrenching article on addiction this morning –and the trouble that many addicts have at getting their insurance plans to pay for drugs used to treat addiction.  The article opens with a pregnant woman facing a second prior authorization in a month; additional anecdotes include a woman who lost her 22 year old son days to a heroin overdose days before an appointment on a new insurance plan that would have covered treatment, and a grateful father of twin five year old boys whose Medicaid plan covers methadone.
From the article:
Six years after the passage of the Affordable Care Act, no state covers all of the substance use disorder treatments required by the law without harmful treatment limitations, a report out this summer by the National Center on Addiction and Substance Abuse found.

This is a real problem.   Addicts are often not nearly organized enough to navigate a complex bureaucratic system to get prior authorizations every month for drugs they may need for the rest of their lives.   The drugs aren’t cheap, either.  Suboxone costs over $5000 a year, and the new six month  implantable version will cost almost $10,000  a year.   Methadone is a bargain at under $100 a year, and Vivitrol, a monthly injection of a drug which causes withdrawal symptoms of addicts use narcotics, costs about $15,000 a year.   19 Americans die of a drug overdose each hour, and the states with the highest rates of drug addiction often have the lowest rate of public funding for substance abuse medications.

The answer posed by those interviewed, including former Representative Patrick Kennedy who coauthored the Mental Health Parity and Addiction Equity Act, is that insurance plans should fully cover all medications used to treat substance abuse. 

I’m sympathetic to this – it’s lunacy to require patients to “fail” at one medication before trying the one recommended by their physician – especially when failure means going back to illicit narcotic use, with a high risk of overdose and death. The stakes are very high here.

There’s a flip side, though.   There is little to counterbalance drug company imperatives to increase prices.  Indeed, some of the organizations pushing for a requirement that all health plans cover all medications are likely to get substantial funding from the pharmaceutical industry.   We need to figure out how to insure access to these life-saving drugs while not causing health care costs to continue to escalate.  We could do this by purchasing these medications through public entities and removing this coverage from the private insurance markets, much as many states do with vaccines.   The public health imperative is large and getting larger. But alone among developed countries we’ve been reluctant to have the government play a role in pharmaceutical pricing.   We must think about ways to make these medications simultaneously affordable to both the system and to individuals in need.